Celgene was one of the best performers in the biotech group for 2013. So far this year the stock continues to perform well; during the January swoon, it barely budged. The current price is perched on the handle of a very deep cup/handle pattern, pulling back from the recent surge toward 170. This recent consolidation is healthy to see before another push higher. The group of biotech stocks has been relentless, and Celgene has been a leader. Adding an April call other other day allows us to be patient.
